• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Kv11.1 离子通道上的长 QT2 突变通过消除蛋白激酶 Cα 共有位点来抑制电流活性。

Long QT2 mutation on the Kv11.1 ion channel inhibits current activity by ablating a protein kinase Cα consensus site.

机构信息

Departments of Molecular Pharmacology and Therapeutics, Loyola University, Chicago, Illinois, USA.

出版信息

Mol Pharmacol. 2012 Sep;82(3):428-37. doi: 10.1124/mol.112.077966. Epub 2012 May 31.

DOI:10.1124/mol.112.077966
PMID:22653970
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6673708/
Abstract

Mutations that inhibit Kv11.1 ion channel activity contribute to abnormalities of cardiac repolarization that can lead to long QT2 (LQT2) cardiac arrhythmias and sudden death. However, for most of these mutations, nothing is known about the molecular mechanism linking Kv11.1 malfunction to cardiac death. We have previously demonstrated that disease-related mutations that create consensus sites for kinases on ion channels can dramatically change ion channel activity. Here, we show that a LQT2-associated mutation can inhibit Kv11.1 ion channel activity by perturbing a consensus site for the Ser/Thr protein kinase C α (PKCα). We first reveal by mass spectrometry analysis that Ser890 of the Kv11.1 ion channel is phosphorylated. Then, we demonstrate by a phospho-detection immunoassay combined with genetic manipulation that PKCα phosphorylates Ser890. Furthermore, we show that Ser890 phosphorylation is associated with an increase in Kv11.1 membrane density with alteration of recovery from inactivation. In addition, a newly discovered and as yet uncharacterized LQT2-associated nonsynonymous single nucleotide polymorphism 2660 G→A within the human ether-á-go-go-related gene 1 coding sequence, which replaces arginine 887 with a histidine residue (R887H), strongly inhibits PKCα-dependent phosphorylation of residue Ser890 on Kv11.1, and ultimately inhibits surface expression and current density. Taken together, our data provide a functional link between this channel mutation and LQT2.

摘要

导致心脏复极化异常的抑制 Kv11.1 离子通道活性的突变可导致长 QT2(LQT2)心律失常和猝死。然而,对于这些突变中的大多数,我们并不知道将 Kv11.1 功能障碍与心脏死亡联系起来的分子机制。我们之前已经证明,在离子通道上为激酶创建共识位点的与疾病相关的突变可以显著改变离子通道活性。在这里,我们表明,与 LQT2 相关的突变可以通过扰乱丝氨酸/苏氨酸蛋白激酶 Cα(PKCα)的共识位点来抑制 Kv11.1 离子通道活性。我们首先通过质谱分析揭示 Kv11.1 离子通道的 Ser890 被磷酸化。然后,我们通过磷酸化检测免疫测定结合遗传操作证明 PKCα磷酸化 Ser890。此外,我们表明 Ser890 磷酸化与 Kv11.1 膜密度的增加有关,同时改变了失活后的恢复。此外,我们在人类 ether-á-go-go-related 基因 1 编码序列中发现了一个新的、尚未表征的与 LQT2 相关的非同义单核苷酸多态性 2660 G→A,该突变将精氨酸 887 替换为组氨酸残基(R887H),强烈抑制 Kv11.1 上 PKCα依赖性 Ser890 磷酸化,最终抑制表面表达和电流密度。总之,我们的数据为该通道突变与 LQT2 之间提供了一个功能联系。

相似文献

1
Long QT2 mutation on the Kv11.1 ion channel inhibits current activity by ablating a protein kinase Cα consensus site.Kv11.1 离子通道上的长 QT2 突变通过消除蛋白激酶 Cα 共有位点来抑制电流活性。
Mol Pharmacol. 2012 Sep;82(3):428-37. doi: 10.1124/mol.112.077966. Epub 2012 May 31.
2
Mechanistic basis for type 2 long QT syndrome caused by KCNH2 mutations that disrupt conserved arginine residues in the voltage sensor.电压传感器中保守精氨酸残基突变导致 KCNH2 突变的 2 型长 QT 综合征的发病机制。
J Membr Biol. 2013 May;246(5):355-64. doi: 10.1007/s00232-013-9539-6. Epub 2013 Apr 2.
3
Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism.大多数LQT2突变通过2类(运输缺陷)机制降低Kv11.1(hERG)电流。
Circulation. 2006 Jan 24;113(3):365-73. doi: 10.1161/CIRCULATIONAHA.105.570200.
4
Trafficking defect and proteasomal degradation contribute to the phenotype of a novel KCNH2 long QT syndrome mutation. trafficking 缺陷和蛋白酶体降解导致一种新型 KCNH2 长 QT 综合征突变表型。
PLoS One. 2011 Mar 31;6(3):e18273. doi: 10.1371/journal.pone.0018273.
5
Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum.药理学纠正 KCNH2(hERG)中的长 QT 相关突变可增加储存于内质网中的 Kv11.1 通道的转运。
Am J Physiol Cell Physiol. 2013 Nov 1;305(9):C919-30. doi: 10.1152/ajpcell.00406.2012. Epub 2013 Jul 17.
6
C-terminal HERG (LQT2) mutations disrupt IKr channel regulation through 14-3-3epsilon.C 端 HERG(长 QT 综合征 2 型)突变通过 14-3-3ε破坏 IKr 通道调节。
Hum Mol Genet. 2006 Oct 1;15(19):2888-902. doi: 10.1093/hmg/ddl230. Epub 2006 Aug 21.
7
The human ERG1 channel polymorphism, K897T, creates a phosphorylation site that inhibits channel activity.人类ERG1通道多态性K897T产生了一个抑制通道活性的磷酸化位点。
Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14704-8. doi: 10.1073/pnas.0802250105. Epub 2008 Sep 12.
8
Overlapping LQT1 and LQT2 phenotype in a patient with long QT syndrome associated with loss-of-function variations in KCNQ1 and KCNH2.长 QT 综合征患者中 LQT1 和 LQT2 表型重叠,与 KCNQ1 和 KCNH2 功能丧失变异相关。
Can J Physiol Pharmacol. 2010 Dec;88(12):1181-90. doi: 10.1139/Y10-094.
9
The role of CAV3 in long-QT syndrome: clinical and functional assessment of a caveolin-3/Kv11.1 double heterozygote versus caveolin-3 single heterozygote.CAV3在长QT综合征中的作用:小窝蛋白-3/Kv11.1双杂合子与小窝蛋白-3单杂合子的临床及功能评估
Circ Cardiovasc Genet. 2013 Oct;6(5):452-61. doi: 10.1161/CIRCGENETICS.113.000137. Epub 2013 Sep 10.
10
C-terminal β9-strand of the cyclic nucleotide-binding homology domain stabilizes activated states of Kv11.1 channels.环核苷酸结合同源结构域的C末端β9链稳定Kv11.1通道的激活状态。
PLoS One. 2013 Oct 25;8(10):e77032. doi: 10.1371/journal.pone.0077032. eCollection 2013.

本文引用的文献

1
PKC-ing is believing: targeting protein kinase C in heart failure.蛋白激酶C可信:心力衰竭中靶向蛋白激酶C
Circ Res. 2011 Dec 9;109(12):1320-2. doi: 10.1161/CIRCRESAHA.111.259358.
2
Post-transcriptional control of human ether-a-go-go-related gene potassium channel protein by alpha-adrenergic receptor stimulation.α-肾上腺素能受体刺激对人 ether-a-go-go 相关基因钾通道蛋白的转录后调控。
Mol Pharmacol. 2010 Aug;78(2):186-97. doi: 10.1124/mol.109.062216. Epub 2010 May 12.
3
Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach.蛋白激酶Cα而非蛋白激酶Cβ或蛋白激酶Cγ调节收缩性和心力衰竭易感性:鲁比前列酮作为一种新型治疗方法的意义。
Circ Res. 2009 Jul 17;105(2):194-200. doi: 10.1161/CIRCRESAHA.109.195313. Epub 2009 Jun 25.
4
Role for protein kinase C-alpha in keratinocyte growth arrest.蛋白激酶C-α在角质形成细胞生长停滞中的作用。
J Invest Dermatol. 2009 Oct;129(10):2365-75. doi: 10.1038/jid.2009.74. Epub 2009 Apr 2.
5
Protein kinase C in heart failure: a therapeutic target?心力衰竭中的蛋白激酶C:一个治疗靶点?
Cardiovasc Res. 2009 May 1;82(2):229-39. doi: 10.1093/cvr/cvp001. Epub 2009 Jan 24.
6
The human ERG1 channel polymorphism, K897T, creates a phosphorylation site that inhibits channel activity.人类ERG1通道多态性K897T产生了一个抑制通道活性的磷酸化位点。
Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14704-8. doi: 10.1073/pnas.0802250105. Epub 2008 Sep 12.
7
Stimulation of N-terminal truncated isoform of androgen receptor stabilizes human ether-á-go-go-related gene-encoded potassium channel protein via activation of extracellular signal regulated kinase 1/2.雄激素受体N端截短异构体的刺激通过激活细胞外信号调节激酶1/2来稳定人醚-á-去极化相关基因编码的钾通道蛋白。
Endocrinology. 2008 Oct;149(10):5061-9. doi: 10.1210/en.2007-1802. Epub 2008 Jul 3.
8
Protein kinase C inhibits caveolae-mediated endocytosis of TRPV5.蛋白激酶C抑制小窝介导的瞬时受体电位香草酸亚型5(TRPV5)的内吞作用。
Am J Physiol Renal Physiol. 2008 May;294(5):F1212-21. doi: 10.1152/ajprenal.00007.2008. Epub 2008 Feb 27.
9
PKC isozymes in chronic cardiac disease: possible therapeutic targets?慢性心脏疾病中的蛋白激酶C同工酶:可能的治疗靶点?
Annu Rev Pharmacol Toxicol. 2008;48:569-99. doi: 10.1146/annurev.pharmtox.48.121806.154902.
10
Effects of protein kinase C activation on cardiac repolarization and arrhythmogenesis in Langendorff-perfused rabbit hearts.蛋白激酶C激活对Langendorff灌注兔心脏复极化及心律失常发生的影响。
Europace. 2007 Nov;9(11):1094-8. doi: 10.1093/europace/eum160. Epub 2007 Aug 7.